viewRecce Pharmaceuticals Ltd

Recce’s anti-cancer compound appears to be well tolerated

Recce Ltd’s (ASX:RCE) share price has increased after receiving positive toxicology results from a dose escalation study of its lead compound RECCE 327, in a mouse with cancer.

Recce Ltd’s anti-cancer compound appears to be well tolerated

The company’s shares were last trading at $0.20, up 11% intraday.

The initial results from the study has indicated that treatment with RECCE 327 was tolerated without animal deaths at both doses tested.

RECCE 327 is an antibiotic and anti-cancer drug that fights against viruses and bacteria, including superbugs, even after repeated use.

Recce is compiling pre-clinical efficacy and toxicology data across several anti-bacterial, anti-cancer and anti-viral models.

This is part of its planned Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) in the first half of CY2017.

The latest data is encouraging and supports the continuation of the current test protocols.

While there was no significant inhibition of growth in the cancer cells, the good toxicology data should give Recce the confidence to continue dosing RECCE 327 in mice.

The pre-clinical studies are on track to be completed by April 2017.

Quick facts: Recce Pharmaceuticals Ltd

Price: 0.75 AUD

Market: ASX
Market Cap: $102.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Recce Pharmaceuticals Ltd named herein, including the promotion by the Company of Recce Pharmaceuticals Ltd in any Content on the Site, the...



Recce Pharmaceuticals on track to develop synthetic antibiotics targeting...

Recce Pharmaceuticals Ltd (ASX:RCE) executive director James Graham tells Proactive Investors the company is on the verge of developing a new class of synthetic antibiotics to counter antibiotic resistance.   As fears of superbugs may one day reach pandemic proportions, Graham...

on 29/5/19

2 min read